Table 3.

Multivariate logistic regression analysis for potential predictors of major adverse carediovascular events at three-year follow-up

	Univariate analysis		Multivariate analysis
	OR (95%CI)	p value	OR (95%CI)	p-value
First Model¶
Age, years	1.079 (0.951- 1.225)	0.239
Male	2.420 (0.569-10.292)	0.231
Family history	5.056 (1.720-14.861)	0.003	5.972 (1.449-24.615)	0.013
Hyperlipidemia	1.142 (0.435-2.994)	0.788
Diabetes mellitus	3.481 (1.026-11.810)	0.045	5.194 (0.884-30.540)	0.068
Hypertension	2.323 (0.878-6.142)	0.089	3.271 (0.823-12.998)	0.092
Culprit artery*	4.583 (1.434-14.650)	0.010	2.959 (0.604-14.498)	0.181
LVEF, %	0.878 (0.823-0.938)	< 0.001	0.832 (0.761-0.909)	< 0.001
Creatinine, mg/dl	0.828 (0.051-13.450)	0.894
Asp agg. time (AU x min)	1.002 (1.000-1.003)	0.078	1.000 (0.998-1.003)	0.838
Clop agg time (Au x min)	1.002 (1.000-1.004)	0.041	1.003 (1.000-1.006)	0.022
Second Model†
Responder‡	Ref.	Ref.	Ref.	Ref.
Asp res‡	2.647 (0.539-12.992)	0.230	2.075 (0.503-8.549)	0.312
Clop res‡	4.167 (1.011-17.175)	0.048	4.056 (0.618 -25.612)	0.065
Dual res‡	15.000 (3.666-61.366)	<0.001	3.334 (0.484-22.954)	0.002

CI: confidence interval; LVEF: left ventricular ejection fraction; Asp: aspirin; Clop: Clopidogrel; agg; aggregation; min: minute; AU: aggregation unit; res: resistant; MACE: major adverse cardiovascular events; OR: odds ratio.

^*Culprit artery was divided as left anterior descending artery (LAD) and non-LAD (circumflex artery and right coronary artery);

^‡These groups were included in a second model instead of aspirin and clopidogrel aggregation time;

^¶Nagelkerke R square of the first model was 49.2%;

^†Nagelkerke R square of the second model was 59.4%.